Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Sell
47
PDSB Quote, Financials, Valuation and Earnings
Last price:
$1.79
Seasonality move
:
10.18%
Day range:
$1.71 - $1.82
52-week range:
$0.85 - $4.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.64x
Volume:
288.6K
Avg. volume:
700.3K
1-year change:
-36.09%
Market cap:
$81.4M
Revenue:
--
EPS (TTM):
-$0.94
Analysts' Opinion
-
Consensus RatingPDS Biotechnology has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.50, PDS Biotechnology has an estimated upside of 321.35% from its current price of $1.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.50 representing 100% downside risk from its current price of $1.78.
Fair Value
-
According to the consensus of 2 analysts, PDS Biotechnology has 321.35% upside to fair value with a price target of $7.50 per share.
PDSB vs. S&P 500
-
Over the past 5 trading days, PDS Biotechnology has overperformed the S&P 500 by 3.91% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PDS Biotechnology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PDS Biotechnology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PDS Biotechnology reported revenues of --.
Earnings Growth
-
PDS Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PDS Biotechnology reported earnings per share of -$0.21.
Enterprise value:
60.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$42.6M | -$43.7M | -$35.3M | -$10.1M | -$9.1M | |
| EBITDA | -$41M | -$40.9M | -$33.1M | -$9.4M | -$8.7M | |
| Diluted EPS | -$1.45 | -$1.37 | -$0.94 | -$0.30 | -$0.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $27.3M | $60.7M | $68M | $68.7M | $42.5M | |
| Total Assets | $27.8M | $61M | $68.4M | $69M | $47M | |
| Current Liabilities | $2.9M | $5M | $4.1M | $15.1M | $18.3M | |
| Total Liabilities | $3.4M | $5.2M | $27.4M | $31.8M | $24.7M | |
| Total Equity | $24.4M | $55.9M | $41M | $37.2M | $22.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.5M | -$30.4M | -$34.1M | -$9.9M | -$9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $38.8M | $31.8M | $7.5M | $20M | $7.3M | |
| Free Cash Flow | -$32.5M | -$30.4M | -$34.1M | -$9.9M | -$9M | |
PDSB
Sector
Market Cap
$81.4M
$32.6M
Price % of 52-Week High
40.27%
47.07%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-36.09%
-37.62%
Beta (5-Year)
1.272
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.71
200-day SMA
Sell
Level
$2.01
Bollinger Bands (100)
Buy
Level
1.16 - 1.56
Chaikin Money Flow
Sell
Level
-83.1M
20-day SMA
Buy
Level
$1.59
Relative Strength Index (RSI14)
Buy
Level
65.54
ADX Line
Buy
Level
33.01
Williams %R
Neutral
Level
-23.0769
50-day SMA
Buy
Level
$1.34
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
133.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Stock Forecast FAQ
In the current month, PDSB has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PDSB average analyst price target in the past 3 months is $7.50.
-
Where Will PDS Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that PDS Biotechnology share price will rise to $7.50 per share over the next 12 months.
-
What Do Analysts Say About PDS Biotechnology?
Analysts are divided on their view about PDS Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PDS Biotechnology is a Sell and believe this share price will drop from its current level to $4.50.
-
What Is PDS Biotechnology's Price Target?
The price target for PDS Biotechnology over the next 1-year time period is forecast to be $7.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PDSB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PDS Biotechnology is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PDSB?
You can purchase shares of PDS Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PDS Biotechnology shares.
-
What Is The PDS Biotechnology Share Price Today?
PDS Biotechnology was last trading at $1.79 per share. This represents the most recent stock quote for PDS Biotechnology. Yesterday, PDS Biotechnology closed at $1.78 per share.
-
How To Buy PDS Biotechnology Stock Online?
In order to purchase PDS Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is up 28.33% over the past day.
Buy
75
ARQQ alert for Jun 17
Arqit Quantum [ARQQ] is up 2.51% over the past day.
Buy
59
SYM alert for Jun 17
Symbotic [SYM] is down 1.14% over the past day.
